title: Treatment of congestive heart failure: present and future.
abstract: The treatment of patients with congestive heart failure has markedly improved over the past 25 years. The most successful therapy has been attenuation of neurohumoral overactivation with antagonists of the renin-angiotensin-aldosterone system, as well as beta-adrenergic blockade. Cardiac surgical interventions, which include not only aortocoronary artery bypass surgery but also interventions that remodel the heart and repair the mitral valve, have also been advocated. However, randomized clinical trials to prove their benefit and to identify which patients could derive the most benefit from these interventions are lacking. Cardiac devices, such as biventricular pacemakers (for cardiac resynchronization) and implantable cardiac defibrillators, have proved useful in improving survival and quality of life. The treatment of sleep apnea with continuous positive airway pressure has shown some promise, as has immune modulation therapy, but more research to conclusively prove their efficacy is necessary. Cell therapy with skeletal myoblasts or pluripotential stem cells is an interesting and emerging area of research that shows enormous promise. However, fundamental questions regarding the optimal use of this therapy remain unanswered. Finally, although exciting, these developments, along with the changing demographics of the Canadian population, will require a change in the way we provide care for patients with congestive heart failure. These changes will require greater involvement of health care professionals other than physicians, and greater emphasis on outpatient care, early detection and prevention, and evidence-based practice.
authors.affiliation: Research Centre, Montreal Heart Institute, Quebec, Canada. jean-rouleau@umontreal.ca
authors.forename: Jean-Lucien
authors.initials: JL
authors.lastname: Rouleau
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000191:economics / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use; D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D006348:Cardiac Surgical Procedures / Q000191:economics / Q000639:trends; D064987:Cell- and Tissue-Based Therapy / Q000191:economics / Q000639:trends; D017147:Defibrillators, Implantable / Q000191:economics / Q000639:trends; D065128:Endothelin Receptor Antagonists; D006333:Heart Failure / Q000191:economics / Q000628:therapy*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists; D017466:Receptors, Endothelin / Q000627:therapeutic use; D018161:Receptors, Mineralocorticoid / Q000627:therapeutic use; D017483:Receptors, Vasopressin / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D065092:Antidiuretic Hormone Receptor Antagonists; D065128:Endothelin Receptor Antagonists; D000451:Mineralocorticoid Receptor Antagonists; D017466:Receptors, Endothelin; D018161:Receptors, Mineralocorticoid; D017483:Receptors, Vasopressin